Peptide radiotracers are radioactive tags attached to peptides that seek out receptors on tumor cells, so scanners can map cancer and, with stronger isotopes, treat it. The quick answer: gallium-68 DOTATATE, a somatostatin-mimicking peptide, detected 95% of neuroendocrine tumor lesions in a 131-patient study, vs 31% for the older indium-111 scan,[2] and its therapy twin, lutetium-177 dotatate, is FDA-approved after a positive phase 3 trial.[5][6] PSMA agents for prostate cancer work the same way but are small molecules, not peptides.[9]
This page is part of our peptide basics hub. Radioactive therapies are one type of peptide-drug conjugate.
Bottom line
- Established: somatostatin receptor PET with Ga-68 or Cu-64 DOTATATE is the standard scan for most neuroendocrine tumors.[1]
- Established: lutetium-177 dotatate slows neuroendocrine tumor growth in randomized phase 3 trials.[5][7]
- Important distinction: PSMA imaging and Lu-177 PSMA-617 are small-molecule agents.[9]
- Emerging: alpha-emitting peptide therapies are in phase 2.[13]
How peptide radiotracers work
Many neuroendocrine tumors (NETs), which arise from hormone-producing cells in the gut, pancreas and lungs, are covered in somatostatin receptors. Octreotide-like peptides bind those receptors tightly. Chemists attach a “chelator” such as DOTA, a molecular cage that grips a radioactive metal.[1]
- Imaging (diagnosis): a short-lived positron emitter, gallium-68 or copper-64, lets a PET scanner show where the peptide collects.
- Therapy (treatment): swapping in lutetium-177, which emits beta particles that damage nearby cells, turns the same peptide into a targeted radiation treatment.
Using one target for both scanning and treatment is called “theranostics.” A positive scan helps identify who may benefit from the therapy. The peptides used are ring-shaped; see our guide to cyclic peptides.
Peptide or small molecule? Common agents compared
| Agent | Target | Use | Peptide? | FDA status |
|---|---|---|---|---|
| Ga-68 DOTATATE | Somatostatin receptors | PET imaging of NETs | Yes | Approved 2016[3] |
| Cu-64 DOTATATE | Somatostatin receptors | PET imaging of NETs | Yes | Approved 2020[4] |
| Lu-177 dotatate | Somatostatin receptors | NET therapy | Yes | Approved 2018[6] |
| Lu-177 edotreotide | Somatostatin receptors | NET therapy | Yes | Phase 3 positive[8] |
| Ga-68 gozetotide (PSMA-11) | PSMA | Prostate cancer PET | No, urea-based small molecule | Approved 2022[14] |
| Lu-177 PSMA-617 | PSMA | Prostate cancer therapy | No, urea-based small molecule | Approved 2022[12] |
The PSMA agents grew out of a medicinal chemistry program built around a glutamate-urea scaffold. They are sometimes loosely grouped with peptides because they are made from amino acid building blocks, but chemists treat them as small-molecule ligands.[9]
Key imaging studies
Ga-68 DOTATATE vs older scans. In a prospective NIH study of 131 patients with gastroenteropancreatic NETs or unknown primary tumors, Ga-68 DOTATATE PET/CT found 95.1% of lesions, compared with 45.3% for CT or MRI and 30.9% for indium-111 pentetreotide SPECT/CT. The scan changed the treatment plan for about one in three patients.[2] Current US and European guidelines describe how to use somatostatin receptor PET for diagnosis, staging and selecting patients for therapy.[1]
PSMA PET (proPSMA). For comparison, in 302 men with high-risk prostate cancer, PSMA PET-CT was 92% accurate at finding spread vs 65% for CT plus bone scan, and it changed management more often.[10]
Key therapy trials
NETTER-1. In 229 patients with advanced midgut NETs that had progressed on standard drugs, the estimated 20-month progression-free rate was 65.2% with lutetium-177 dotatate vs 10.8% with high-dose octreotide. Response rates were 18% vs 3%. Severe drops in blood counts were uncommon, and no kidney toxicity was seen during the observed period.[5]
NETTER-2. In 226 patients with newly diagnosed, higher grade 2-3 gastroenteropancreatic NETs, adding lutetium-177 dotatate as first treatment extended median progression-free survival from 8.5 to 22.8 months.[7]
COMPETE. In 309 patients, lutetium-177 edotreotide, a closely related peptide, produced median progression-free survival of 23.9 months vs 14.1 months with everolimus, a standard tablet treatment.[8]
VISION (small molecule, for contrast). In 831 men with PSMA-positive metastatic castration-resistant prostate cancer, Lu-177 PSMA-617 extended median overall survival from 11.3 to 15.3 months.[11]
What to expect
Scan. A DOTATATE PET scan involves an IV injection, a wait while the tracer spreads through the body, and then the scan itself. Because octreotide and lanreotide compete for the same receptors, guidelines address how to time the scan around these medicines, so tell the imaging team about any somatostatin analog injections you receive.[1]
Treatment. In NETTER-1, lutetium-177 dotatate was given as four IV infusions of 7.4 GBq, eight weeks apart, alongside octreotide.[5] Follow-up scans and blood tests check response and safety. A clinician decides whether a patient is a candidate, usually based on a positive somatostatin receptor scan.[1]
Side effects and safety
Diagnostic scans use tiny amounts of peptide and a modest radiation dose. Therapy is different: lutetium treatments can lower blood counts and expose kidneys and bone marrow to radiation, so patients receive kidney-protecting amino acid infusions and blood monitoring.[5][6][7] Radiation safety precautions at home are usually advised for a short time after treatment.
Limitations
- Not every NET carries enough somatostatin receptors; poorly differentiated tumors may not show up.[1]
- Most therapy trials measured progression-free survival rather than overall survival.
- Many trials were open-label and sponsored by manufacturers.
What’s next
Researchers are testing alpha-emitting isotopes, which deliver more energy over a shorter distance. A phase 2 trial of lead-212 DOTAMTATE in NETs enrolled 69 patients and is active, not recruiting.[13] Peptides targeting other receptors, such as the GLP-1 receptor in insulin-secreting tumors and pancreatic beta cells, are being studied for imaging. For other ways peptides are used against cancer, see our guide to peptide vaccines, and for how such peptides are designed, natural vs synthetic peptides.
Questions to discuss with a clinician
- Would a somatostatin receptor PET scan help stage my tumor?
- Is my tumor receptor-positive enough for lutetium therapy?
- What are the kidney and blood count risks, and how will I be monitored?
- What radiation precautions should I take at home after treatment?
